Dataset Information
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study.
Ontology highlight
ABSTRACT: Purpose
A cryptic inv(16)(p13.3q24.3) encoding the CBFA2T3-GLIS2 fusion is associated with poor outcome in infants with acute megakaryocytic leukemia. We aimed to broaden our understanding of the pathogenesis of this fusion through transcriptome profiling.Experimental design
Available RNA from children and young adults with de novo acute myeloid leukemia (AML; N = 1,049) underwent transcriptome sequencing (mRNA and miRNA). Transcriptome profiles for those with the CBFA2T3-GLIS2 fusion (N = 24) and without (N = 1,025) were contrasted to define fusion-specific miRNAs, genes, and pathways. Clinical annotations defined distinct fusion-associated disease characteristics and outcomes.Results
The CBFA2T3-GLIS2 fusion was restricted to infants <3 years old (P < 0.001), and the presence of this fusion was highly associated with adverse outcome (P < 0.001) across all morphologic classifications. Further, there was a striking paucity of recurrent cooperating mutations, and transduction of cord blood stem cells with this fusion was sufficient for malignant transformation. CBFA2T3-GLIS2 positive cases displayed marked upregulation of genes with cell membrane/extracellular matrix localization potential, including NCAM1 and GABRE. Additionally, miRNA profiling revealed significant overexpression of mature miR-224 and miR-452, which are intronic miRNAs transcribed from the GABRE locus. Gene-set enrichment identified dysregulated Hippo, TGF?, and hedgehog signaling, as well as NCAM1 (CD56) interaction pathways. Therapeutic targeting of fusion-positive leukemic cells with CD56-directed antibody-drug conjugate caused significant cytotoxicity in leukemic blasts.Conclusions
The CBFA2T3-GLIS2 fusion defines a highly refractory entity limited to infants that appears to be sufficient for malignant transformation. Transcriptome profiling elucidated several highly targetable genes and pathways, including the identification of CD56, providing a highly plausible target for therapeutic intervention.
SUBMITTER: Smith JL
PROVIDER: S-EPMC7002196 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
Publications
Comprehensive Transcriptome Profiling of Cryptic <i>CBFA2T3-GLIS2</i> Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study.
Clinical cancer research : an official journal of the American Association for Cancer Research 20191112 3
<h4>Purpose</h4>A cryptic inv(16)(p13.3q24.3) encoding the <i>CBFA2T3-GLIS2</i> fusion is associated with poor outcome in infants with acute megakaryocytic leukemia. We aimed to broaden our understanding of the pathogenesis of this fusion through transcriptome profiling.<h4>Experimental design</h4>Available RNA from children and young adults with <i>de novo</i> acute myeloid leukemia (AML; <i>N</i> = 1,049) underwent transcriptome sequencing (mRNA and miRNA). Transcriptome profiles for those wit ...[more]
